ARTICLE SUMMARY:
Uptake of companion diagnostics is increasing across oncology, with new diagnostic entrants, armed with next-generation technologies, seeking to upend the current, somewhat shaky business models with higher-value deals.
Companion diagnostics have certainly seen growing interest in recent years. This regulatory category establishes coordinated FDA review of a drug and an associated diagnostic test used to determine which patients are most likely to benefit from the drug.
